芪苈强心胶囊联合环磷腺苷葡胺治疗慢性心衰的临床研究

目的 探讨芪苈强心胶囊联合环磷腺苷葡胺治疗慢性心力衰竭的临床疗效。方法 选择衡水市第五人民医院内科2013年2月-2015年2月收治的慢性心力衰竭患者82例,随机分为治疗组和对照组,每组各41例。对照组在常规治疗的基础上静脉滴注环磷腺苷葡胺注射液120 mg,1次/d。治疗组在对照组的基础上服用芪苈强心胶囊,4粒/次,3次/d。两组疗程均为2个月。比较两组的临床疗效、6分钟步行距离(6MWD)、左室射血分数(LVEF)以及心衰生化指标肌钙蛋白T(cTnT)、氨基末端B型脑利钠肽前体(NT-proBNP)、血清类胰岛素生长因子-1(IGF-1)、高敏C反应蛋白(hs-CRP)和同型半胱氨酸(Hcy)。结果 治疗组总有效率(95.12%)明显高于对照组(80.48%),两组比较差异具有统计学意义(P < 0.05);治疗后,两组的6MWD、LVEF显著高于同组治疗前,且治疗组高于对照组,两组比较差异具有统计学意义(P < 0.05)。治疗后,两组的cTnT、NT-proBNP、hs-CRP、Hcy显著低于同组治疗前,IGF-1显著高于治疗前,且比较差异有统计学意义(P < 0.05);治疗后,治疗组的cTnT、NT-proBNP、hs-CRP、Hcy显著低于对照组,IGF-1显著高于对照组,且比较差异具有统计学意义(P < 0.05)。结论 芪苈强心胶囊联合环磷腺苷葡胺治疗慢性心衰具有较好的临床疗效,且能够改善慢性心衰的观察指标。

Clinical study on Qili Qiangxin Capsules combined with meglumine adenosine cyclophosphate in treatment of chronic heart failure

Objective To investigate the clinical effect of Qili Qiangxin Capsules combined with meglumine adenosine cyclophosphate in treatment of chronic heart failure. Methods Patients (82 cases) with chronic heart failure in the Fifth People's Hospital of Hengshui from February 2013 to February 2015 were randomly divided into control and treatment groups. Each group had 41 cases. Patients in control group were iv Meglumine Adenosine Cyclophosphate Injections on the basis of conventional therapy 120 mg, once dialy. Patients in treatment group were given Qili Qiangxin Capsules 4 pills/time, three times daily. The patients in two groups were treated for 2 months. The efficacy, 6-minute walk distance (6MWD), left ventricular ejection fraction (LVEF), and biochemical indicators of heart failure cardiac troponin (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP), insulin-like growth factor-1 (IGF-1), high-sensitivity C-reactive protein (hs-CRP) and homocysteine (Hcy) between patients of two groups were compared. Results The clinical efficacy in treatment group (95.12%) was higher than that in control group (80.48%) with significant difference (P < 0.05). After treatment, 6MWD and LVEF were significantly higher than those of same group before treatment. And 6MWD and LVEF in treatment group were higher than those in control group, and the difference was statistically significant (P < 0.05). After treatment, the levels of cTnT, NT-proBNP, hs-CRP, and Hcy of two groups were significantly lower than those before treatment with significant differences (P < 0.05). The level of IGF-1 was significantly higher than that before treatment with significant difference (P < 0.05). The levels of cTnT, NT-proBNP, hs-CRP, and Hcy were significantly lower than those in control group, and the level of IGF-1 was significantly higher than that control group with significant difference (P < 0.05). Conclusion Qili Qiangxin Capsules combined with meglumine adenosine cyclophosphate has good efficacy in treatment of chronic heart failure, and can greatly improve the obvervational index of chronic heart failure.